Who is sponsoring NCT01890902?

NCT01890902 is sponsored by Imprimis Pharmaceuticals, Inc..

What condition does NCT01890902 study?

NCT01890902 studies Acute Pain (Flare) Associated With Osteoarthritis (OA) of the Knee.

What drugs are being tested in NCT01890902?

Interventions: Ketoprofen 10% Cream, Placebo.

What is the status of NCT01890902?

NCT01890902 is currently WITHDRAWN.

Last reviewed 2013-11-08 · How we verify

A Randomized, Multicenter, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Impracor (Ketoprofen 10% Cream) Compared With Placebo in the Treatment of Acute Pain (Flare) Associated With Osteoarthritis of the Knee

NCT01890902 Phase 3 WITHDRAWN

The primary objective of the study is to assess analgesic efficacy of Impracor (Ketoprofen 10% Cream) compared to placebo for acute pain associated with OA flare of the knee.

Details

Lead sponsor	Imprimis Pharmaceuticals, Inc.
Phase	Phase 3
Status	WITHDRAWN
Start date	2013-08

Conditions

Acute Pain (Flare) Associated With Osteoarthritis (OA) of the Knee

Interventions

Ketoprofen 10% Cream
Placebo

Primary outcomes

The primary endpoint will be measured by changes in WOMAC pain subscale scores calculated by comparing baseline WOMAC pain subscale scores on Day 1 to the average WOMAC Pain Subscale scores on Day 4, 6, and 8. — Day 4, 6 and 8